GTC Biotherapeutics (fka GTCB)

[urche]

HIT and HR

I think we should be more rigorous with these terms.

Correct me if I am wrong, but I think there is meaningful clinical difference between HIT (which I understand to be a serious illness in which heparin causes platelets to be destroyed via immune mechanism) and (HR) heparin resistance , the hallmark of which is that usual doses of heparin given prophylactically don't work either as measured by clinical effect or tests of clotting function. If I am thinking about this correctly, HR is a problem for doctors and patients wanting to use heparin prophylactically but not really a disease needing treatment.

I'll do some digging on cost and frequency of use for Argatroban.

Urche